论文部分内容阅读
目的观察干扰素α-2b联合胸腺素α1对乙型肝炎的疗效。方法 145例HBe Ag阳性慢性乙型肝炎患者,随机分为干扰素治疗组65例、联合治疗组40例、对照组40例。干扰素α-2b 600万单位,肌内注射,隔日1次,胸腺素α1(基泰针)1.6 mg皮下注射,2次/周,疗程6个月,观察肝功能、HBV DNA及血清病毒指标。结果治疗结束时,单用干扰素治疗的HBe Ag阳性慢性乙型肝炎患者HBe Ag阴转率为17.5%,而联合胸腺素α1者为24.6%;HBV DNA阴转32.5%,而联合用药组为55.4%。结论胸腺素α1联合干扰素在抗病毒方面起到协同增强作用。
Objective To observe the effect of interferon α-2b and thymosin α1 on hepatitis B virus. Methods A total of 145 HBeAg-positive chronic hepatitis B patients were randomly divided into interferon treatment group (65 cases), combination therapy group (40 cases) and control group (40 cases). Interferon α-2b 6 million units, intramuscular injection, every other day, thymosin α1 (Jitai Acupuncture) 1.6 mg subcutaneously, 2 times / week for 6 months, observe the liver function, HBV DNA and serum viral indicators . Results At the end of treatment, HBe Ag negative conversion rate was 17.5% in HBeAg-positive chronic hepatitis B patients treated with interferon alone compared with 24.6% in combined thymosin α1 and 32.5% in HBV DNA negative patients 55.4%. Conclusions Thymosin α1 combined with interferon plays a synergistic role in antiviral therapy.